CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 99 enrolled
Drug / intervention
pTVG-HP +1 morebiological
Likely dose
pTVG-HP 100 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01341652
NCT01341652Phase 2Completed
CompareCT.gov

Randomized Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) Versus GM-CSF Adjuvant in Patients With Non-Metastatic Prostate Cancer

University of Wisconsin, Madison·interventional·Posted Apr 26, 2011·Updated Jan 20, 2021

In Brief

A Phase 2 clinical trial evaluating pTVG-HP and rhGM-CSF for Prostate Cancer. Completed, enrolled 99 participants across 3 sites.

Detailed Summary

The investigators are trying to find new methods to treat prostate cancer. The approach the investigators are taking is to try to enhance patients' own immune response against the cancer. In this study the investigators will be testing the effectiveness of a vaccine that may be able to help the body fight prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 26, 2011
Enrollment StartMay 23, 2011
Primary CompletionJun 30, 2020
TodayJul 2, 2026
Enrollment to primary: 9.1 yearsPosted 15.2 years ago

Interventions

pTVG-HPbiological

pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period

rhGM-CSFbiological

rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period